| Oct 31 |
Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins
|
| Oct 18 |
Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation
|
| Sep 26 |
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
|
| Aug 19 |
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
|
| Aug 19 |
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
|
| Aug 15 |
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
|
| Aug 15 |
Cocrystal Pharma GAAP EPS of -$0.53 misses by $0.03
|
| Aug 14 |
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
| Jul 19 |
COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…
|
| Jul 18 |
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
|
